Skip to content

Comparison of The Therapeutic Effect of Convalescent Plasma and Plasma-derived Immunoglobulin-enriched solution on COVID-19 Patients

Comparison of The Therapeutic Effect of Convalescent Plasma and Plasma-derived Immunoglobulin-enriched solution on COVID-19 Patients: A Clinical Trial Study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200310046736N1
Enrollment
45
Registered
2020-04-01
Start date
2641-06-14
Completion date
Unknown
Last updated
2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVIDE-19. Other coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention 1: In this intervention group COVID-19 patients who do not reply to routine treatments and are in a critical stage and prolonged hospitalization will be treated with convalescent plasma

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor
Ahvaz University of Medical Sciences
Collaborator

Eligibility

Sex/Gender
All
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: COVID-19 Patients who have the clinical signs of COVIDE-19 infection such as fever, cough, sputum production, sore throat, and so on. Patients with the positive CT scan Patients who declare Informed Consent for this study.

Exclusion criteria

Exclusion criteria: Pregnant Women (based on WHO protocol) Lactating Women (based on WHO protocol) Individuals who exhibit specific allergic reactions to intravenous administration. Patients with/or with a history of dangerous underlying diseases such as IgA deficiency Patients with/or with a history of dangerous diseases such as cardiovascular and or hematological disorders (hemophilia, thalassemia, leukemia). Patients with/or with a history of underlying diseases such as liver and kidney disease Smokers

Design outcomes

Primary

MeasureTime frame
Primary outcome: complete remission of clinical signs of disease. Timepoint: About one week after starting the treatment. Method of measurement: Clinical and laboratory questionnaire.;Negative result for COVID-19 RT-PCR test. Timepoint: About 7-14 days after starting the treatment. Method of measurement: Results of qRT-PCR test.;Normal CT Scan. Timepoint: About 7-14 days after starting the treatment. Method of measurement: Result of CT scan.

Secondary

MeasureTime frame
Recovery and normal levels of biomarkers associated COVID-19. Timepoint: At least 1 to 2 weeks after treatment. Method of measurement: Laboratory Techniques.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMandana Puladzadeh

Ahvaz University of Medical Sciences

parastoomoradi40@yahoo.com+98 61 3373 8283

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 5, 2026